Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Lecce

92 clinical trials in Lecce, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Lecce at a glance
92
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

92 trials in Lecce

Open in trial search

Acute myeloid leukaemia

Recruiting

Study on RVU120 and Venetoclax for Patients with Acute Myeloid Leukemia After Previous Treatment Failure

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Venetoclax
  • Sponsor:Ryvu Therapeutics S.A.

Cataract

Recruiting

Study of levofloxacin, ketorolac trometamol, and dexamethasone eye drops for preventing inflammation and infection after cataract surgery in adults

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Ntc S.r.l.

Ovarian cancer recurrent

Recruiting

Rinatabart Sesutecan plus bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Fallopian tube cancer+2

Recruiting

Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Eli Lilly & Co.

Juvenile idiopathic arthritis

Recruiting

A study to evaluate the safety and effectiveness of filgotinib in children and adolescents aged 8 to 17 years with polyarticular juvenile idiopathic arthritis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Filgotinib
  • Sponsor:Alfasigma S.p.A.

Acute lymphocytic leukaemia

Recruiting

Study of blinatumomab and a drug combination for older adults with newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Asparaginase
  • Sponsor:Amgen Inc.

Cardiac function disturbance postoperative+1

Recruiting

A study to evaluate the effectiveness of R2R01 in preventing acute kidney injury in patients at high risk following heart surgery.

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:R2R01
  • Sponsor:River 2 Renal Corp.

Breast cancer metastatic

Recruiting

A study of palazestrant and ribociclib compared to letrozole and ribociclib for patients with advanced ER+ HER2- breast cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Letrozole
  • Sponsor:Olema Pharmaceuticals Inc.

Cardiac amyloidosis

Recruiting

A Study of Acoramidis in Adult Patients with Transthyretin Amyloidosis with Cardiomyopathy Who Previously Received Tafamidis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acoramidis
  • Sponsor:Bayer Consumer Care AG

Clear cell renal cell carcinoma

Recruiting

A Study Testing Casdatifan and Cabozantinib Compared to Placebo and Cabozantinib in Patients With Advanced Clear Cell Kidney Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:AB521
  • Sponsor:Arcus Biosciences Inc.

Cardiomyopathy

Recruiting

Study of Nucresiran in Adults with Transthyretin Amyloidosis with Cardiomyopathy to Evaluate its Effects on Survival and Heart Problems

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Alnylam Pharmaceuticals Inc.

Squamous cell carcinoma of head and neck

Recruiting

Study of ficerafusp alfa and pembrolizumab as first treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Bicara Therapeutics Inc.

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Lecce

What the registry says about research in the country

01 Oncology Research

Extensive clinical trials focusing on colorectal cancer and innovative treatment approaches combining immunotherapy with established treatments. Studies evaluating new therapeutic strategies for metastatic diseases.

  • Colorectal Cancer Treatments
  • Immunotherapy Combinations
  • Metastatic Disease Management

Multiple studies exploring targeted therapies and novel drug combinations.

02 Hematologic Malignancies

Cutting-edge research in leukemia treatment, including studies on acute myeloid leukemia and chronic myeloid conditions. Innovative approaches testing new drug combinations and treatment strategies.

  • Acute Myeloid Leukemia
  • Chronic Lymphocytic Leukemia
  • Multiple Myeloma

Focus on improving patient outcomes through targeted therapies.

03 Diagnostic Innovation

Advanced research in diagnostic imaging and biomarker studies, particularly in prostate cancer and other solid tumors. Development of precise diagnostic tools for early detection and treatment monitoring.

  • PET Imaging Studies
  • Biomarker Research
  • Treatment Response Assessment

Emphasis on improving diagnostic accuracy and treatment selection.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.